Form 4: PAHC CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Phibro Animal Health's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold 14,080 Class A Common Stock shares through a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported sales of Class A Common Stock.
• A total of 14,080 shares were sold across three transactions on February 19 and February 20, 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On February 19, 2026, 7,040 shares were sold at a weighted average price of $50.2568, with prices ranging from $49.965 to $50.935.
• On February 20, 2026, 6,643 shares were sold at a weighted average price of $51.383, with prices ranging from $50.90 to $51.89.
• Also on February 20, 2026, an additional 397 shares were sold at a weighted average price of $51.9644, with prices ranging from $51.92 to $52.06.
• Following these transactions, BFI Co., LLC indirectly holds 22,600 shares, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a pre-planned 10b5-1 plan mitigates concerns about opportunistic trading based on undisclosed negative information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the transactions were not based on immediate, non-public information.
• The sales occurred at relatively strong price points, ranging from approximately $49.965 to $52.06 per share.

Negatives

• Significant insider selling by a key executive (President and CEO) and a 10% owner could be perceived negatively by the market, potentially signaling a lack of confidence or a desire to diversify holdings.
• The total value of shares sold is substantial, indicating a notable reduction in the insider's exposure to the company's stock.

Risks

• Investor perception risk: Large insider sales, even if pre-planned, can sometimes lead to negative market sentiment or speculation about the company's future prospects.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports past transactions.

Management Comments

• The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider sales, even when pre-planned via a 10b5-1 plan, are common for executives managing personal finances and diversifying portfolios. In the animal health industry, which can be influenced by agricultural cycles and regulatory changes, such sales are typically viewed in the context of the company's broader performance and market conditions rather than as an isolated indicator of distress, especially when executed under a pre-established plan.

Comparison to Industry Standards

• Insider selling is a routine occurrence across all industries, including animal health. For example, executives at Zoetis Inc. (ZTS) or Elanco Animal Health Incorporated (ELAN) also periodically sell shares, often through 10b5-1 plans, for personal financial planning.
• The volume of shares sold by Jack Bendheim and BFI Co., LLC represents a significant monetary value, but without knowing the total outstanding shares or the insider's overall net worth, it's difficult to benchmark against specific peer transactions. However, the use of a 10b5-1 plan aligns with best practices for insiders to avoid accusations of trading on material non-public information.

Related Party Transactions

• The sales were conducted by Jack Bendheim, President and CEO, Director, and 10% Owner, and BFI Co., LLC, a 10% owner over which Jack Bendheim exercises voting and dispositive power. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May interpret the insider sales as a negative signal, potentially leading to short-term downward pressure on the stock price, although the 10b5-1 plan mitigates some of this concern.
• Employees: Unlikely to have a direct impact on employees, but significant insider activity can sometimes affect morale if perceived negatively.

Key Dates

Recommendation

While insider selling by a CEO and 10% owner can be a bearish signal, the execution under a pre-established 10b5-1 plan suggests these are planned financial transactions rather than a reaction to new, negative material information. Investors should monitor future company performance and broader market trends for PAHC, but this specific filing does not provide a strong catalyst for a "buy" or "sell" recommendation beyond maintaining a "hold" position, pending further fundamental analysis.

Keywords

Phibro Animal Health Corp, PAHC, Insider Trading, Form 4, Jack Bendheim, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Animal Health, SEC Filing